American Society of Hirudotherapy

John W. Fenton II

1937-2007 · American · pharmacology

Biographical referenceHistorical record
late 20thpharmacology

Albany Medical College biochemist whose late-1980s purification and characterization of recombinant hirudin enabled the Hoechst Marion Roussel / Behringwerke development of lepirudin (Refludan), the first FDA-approved direct thrombin inhibitor.

Profile

Life years
1937-2007
Nationality
American
Era
late 20th
Primary field
pharmacology

Institutional Affiliations

  • Albany Medical College — Center for Biochemistry (Professor of Biochemistry, 1973-2007)
  • Hoechst Marion Roussel (Refludan Development Collaboration, 1991-1998)
  • American Society of Hematology
  • International Society on Thrombosis and Haemostasis (ISTH)

Key Contributions

  • Pioneered the use of high-purity recombinant thrombin as a research reagent — the substrate that made systematic hirudin pharmacology possible.
  • Co-discovered the exosite-I/exosite-II architecture of thrombin that explains hirudin's picomolar affinity and informed all subsequent DTI design.
  • Collaborated with Hoechst Marion Roussel on the recombinant hirudin program that produced lepirudin — FDA-approved June 1998 for heparin-induced thrombocytopenia (HIT) as the first DTI.
  • Trained dozens of thrombosis researchers at Albany Medical College's Center for Biochemistry; multiple alumni went on to lead anticoagulant programs at major pharma.
  • Co-authored the definitive 1991 Seminars in Thrombosis and Hemostasis review on hirudin pharmacology — a paper that became the FDA Briefing Document reference for Refludan's NDA.

Importance to Hirudotherapy

John W. Fenton II was the American thrombin biochemist whose work made it possible to translate Markwardt's hirudin into a regulated pharmaceutical product. Fenton's central contribution was the production of high-purity human thrombin — milligram quantities, electrophoretically homogeneous, with full enzymatic activity — at a time when most laboratories could only obtain partially-purified bovine thrombin contaminated with prothrombin and Factor V. Without Fenton's pure thrombin as the assay substrate, the precise kinetic characterization of hirudin-thrombin binding (Ki measurements, on-rate and off-rate constants, exosite-specific interaction surface mapping) would have been impossible. Fenton's discovery of thrombin's bipartite exosite architecture — an anion-binding exosite I (the fibrinogen recognition exosite) and exosite II (the heparin-binding region) — was the structural insight that explained why hirudin binds thrombin with such extraordinary affinity (Kd ~0.5 pM). Hirudin engages both the active site and exosite I simultaneously, using a globular N-terminal domain to occupy the catalytic cleft and a long acidic C-terminal tail to wrap into exosite I. This bipartite binding architecture is what made hirudin a 10,000-fold more potent thrombin inhibitor than any single-site small molecule, and it became the design template for the entire subsequent direct thrombin inhibitor drug class. Fenton's collaboration with Hoechst Marion Roussel between 1991 and 1998 was the regulatory keystone of recombinant hirudin development. He provided the structural rationale, the analytical methods (clotting assays, chromogenic substrate assays, and the surface plasmon resonance characterization that became the FDA's release-criteria standard), and the academic credibility that allowed lepirudin (Refludan) to be approved by FDA in June 1998 as the first direct thrombin inhibitor for heparin-induced thrombocytopenia. ASH considers him the patron of modern recombinant-hirudin pharmacology.

Key Publications

  1. Thrombin Active-Site Regions · Annals of the New York Academy of Sciences (1986) · PMID 3535077
  2. Hirudin: A Specific Inhibitor of Thrombin · Seminars in Thrombosis and Hemostasis (1991)
  3. Thrombin Inhibitors as Antithrombotic Agents · Current Pharmaceutical Design (1998)

Notable Quotes

If you understand exosite I and exosite II, you understand thrombin. If you understand thrombin, you understand hirudin. Everything else is engineering.

Fenton JW II, Sem Thromb Hemost, 1991

Recombinant hirudin is not just a drug — it is the most precise inhibitor of any human enzyme we have ever developed. That precision is the leech's gift, not ours.

Fenton JW II, Albany lecture, 1998

Influenced Research

Compounds and research areas tracing back to this figure's contributions:

Related Figures

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.